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Abstract
Background: Single-lead for implantable cardioverter-defibrillator (ICD) with floating atrial sensing 
dipole is a new diagnostic tool with the potential advantage in terms of arrhythmia discrimination. We 
sought to determine whether right heart size and dipole position influence atrial sensing.
Methods: Atrial sensing (AS) amplitude was measured during implantation (PP, periprocedural), 
predischarge (IHFU, in-hospital follow-up) and 3–6 months after the procedure (AFU, ambulatory 
follow-up). Results were related to atrial dipole position in the right atrium (RA) on the basis of chest 
X-ray examination as well as right heart dimensions at echocardiography.
Results: Twenty-four patients were included into final analysis. In 14 (58.3%) patients, sensing dipole 
was located in regions 1 and 2 of the RA. AS amplitude was greater in regions 1 and 2 when com-
pared to other locations (3.15 vs. 1.2 mV, p = 0.045, 7.53 vs. 3.8 mV, p < 0.001 and 5.63 vs. 2.44 mV,  
p = 0.017 for PP measurements, IHFU and AFU, respectively). There was a significant negative corre-
lation between AS-PP and short RA dimension (RADs) (r = –0.56, p = 0.02), AS-IHFU and RA area 
(RAA) (r = –0.45, p < 0.05), AS-AFU and long RA dimension (RADl) (r = –0.46; p = 0.02), AS-AFU 
and RADs (r = –0,48, p = 0.02), and AS-AFU and RAA (and r = –0.52, p < 0.01). There was no 
relationship between AS and other right heart dimensions.
Conclusions: Larger RA size and low sensing dipole location were associated with lower AS amplitude 
in single-lead dual chamber ICD. (Cardiol J 2017; 24, 6: 671–676)
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Introduction
Sudden cardiac death is one of the most com-
mon causes of death in subjects with heart failure 
(HF), irrespective of its etiology [1, 2]. Introduc-
tion of implantable cardioverter-defibrillators 
(ICD) appeared to significantly cut mortality in 
this group of patients, thus implantation of ICDs 
became standard care in secondary and primary 
prevention [3, 4]. Prevalence of supraventricular 
tachyarrhythmias, mainly atrial fibrillation (AF), is 
higher among patients with HF and is associated 
with greater morbidity and mortality [5, 6]. AF is 
also one of the most frequent causes of inappro-
priate therapy in patients with ICDs [7, 8]. Most 
patients enrolled into ICD studies were implanted 
with single-lead devices [9, 10]. However, real life 
data showed that many patients, although they 
do not need atrial pacing, are implanted with ad-
ditional atrial lead which increases specificity in 
arrhythmia diagnosis, but on the other hand, may 
be associated with significant increase in the rate 
of periprocedural complications [11, 12] and mor-
tality [12]. There are some studies showing that 
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data obtained from atrial lead may reduce rates of 
inappropriate therapy although most clinical trials 
provided mixed results in this area [13–15].
Several automatic algorithms using atrial 
sensing were developed to minimize the risk of 
inappropriate therapy [16–18]. Employment of Bio-
tronik’s DX ICD lead systems (defibrillator leads 
with floating atrial sensing dipole) may reduce the 
rate of inappropriate therapies owing to SMART® 
algorithm, so far available only in dual-lead ICDs.
We sought to determine whether right atrium 
(RA) size and/or atrial sensing (AS) rings position 
have an influence on atrial signal amplitude in 
patients with Biotronik’s DX ICDs.
Methods
ICD implantation
Patients with sinus rhythm who met criteria 
for implantation of single-chamber ICD according 
to European Society of Cardiology/European Heart 
Rhythm Association guidelines were considered 
eligible for inclusion into the study. Procedures 
were performed by two experienced operators. 
The technique of ICD implantation with destination 
lead tip location (apex, septum or right ventricle 
outflow tract [RVOT]) was left for discretion of 
the operator. Periprocedural electrical parameters, 
i.a. preamplified atrial sensing amplitude (AS-PP, 
periprocedural atrial sensing), were measured with 
Medtronic Analyzer but achieving acceptable atrial 
signal was not mandatory if ventricular sensing 
and threshold was optimal. One type of defibril-
lation lead was used, Linox ProMRI S DX 65/15, 
i.e. single-coil active fixation lead with AS dipole 
located 15 cm from the lead tip. Two models of ICDs 
were implanted, i.e. Lumax 540 VR-T DX (patients 
1–14) and Iforia 5 VR-T DX (patients 15–24), due 
to changes with time in models availability in our 
center.
Radiographic assessment
To assess AS dipole location standard chest 
X-ray examination in standing position and during 
maximal inspiration was performed. The area of 
interest, i.e. RA and vena cava superior, was divided 
into 6 regions as showed in Figure 1. Each patient 
was assigned to corresponding region according to 
localization of point lying in the middle of distance 
between AS rings.
Echocardiographic assessment
Echocardiographic examination was performed 
using Philips iE33 system (Philips Healthcare, 
Amsterdam, the Netherlands) during hospital stay 
associated with ICD implantation.
Assessment of the right ventricle. To assess 
right ventricular size we took the following steps:
 — measurement of RVOT proximal and distal 
dimensions (in the parasternal long-axis and 
short-axis views);
 — measurement of right ventricular basal, mid-
cavity and longitudinal dimensions (in the 
apical 4-chamber view, adjusted to obtain the 
recommended “right ventricle-focused view”).
All measurements were performed in ac-
cordance with 2010 guidelines of the American 
Society of Echocardiography (ASE), endorsed 
by the European Association of Cardiovascular 
Imaging (formerly European Association of Echo-
cardiography [EAE]) and the Canadian Society of 
Echocardiography (CSE) [19].
Assessment of the right atrium. To assess 
RA size we took the following steps:
 — measurement of RA major/long (RADl) and 
minor/short dimensions (RADs);
 — measurement of RA area (RAA).
Measurements were performed in the standard 
apical 4-chamber view (as shown in Fig. 2), in ac-
cordance with 2010 ASE/EAE/CSE guidelines [19].
Assessment of the left ventricle. For further 
assessment of longitudinal heart size, we addition-
ally measured left ventricular longitudinal dimen-
sion in the standard apical 4-chamber view [20].
ICD follow-up
Complete follow-up of ICD device with as-
sessment of AS was conducted 2–3 days after 
the procedure (IHFU, in-hospital follow-up) and 
3–6 months later (AFU, ambulatory follow-up) as 
a part of routine practice at our institution. Newer 
generation of ICDs used, i.e. Iforia 5 VR-T DX, 
has a possibility to measure the whole range of 
AS amplitude, while Lumax 540 VR-T DX shows 
maximal value of AS at 8.0 mV. To unify results AS 
exceeding 8.0 mV in patients with Iforia 5 VR-T 
DX were reported as 8.0 mV.
All patients included into the study agreed 
for chest X-ray examination, echocardiographic 
study, and periprocedural and during follow-up 
ICD parameters measurements, which were part 
of routine practice in our center.
Results
Twenty-five consecutive patients implant-
ed with Biotronik ICD DX were included into 
the study. One patient died before outpatient 
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follow-up and was not included into the final analy-
sis. Baseline characteristic of study population 
(24 males, mean age 62 ± 13 years) is presented 
Figure 1. Assessment of the sensing dipole position in the right atrium and its influence on atrial sensing amplitude.
in Table 1. In 1 patient, atrial signal amplitude was 
below the minimal measurable value of 0.4 mV 
during AFU.
Figure 2. Echocardiographic assessment of right heart dimensions; 1 — right atrium dimension long; 2 — right atrium 
dimension short; 3 — right atrium area; 4 — right ventricle basal dimension; 5 — right ventricle mid-cavity dimen-
sion; 6 — right ventricle longitudinal dimension; 7 — right ventricular outflow tract proximal dimension; 8 — right 
ventricular outflow tract distal dimension.
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Periprocedural assessment of AS rings posi-
tion was consistent with the results of assessment 
of follow-up chest X-ray and did not change sig-
nificantly comparing two different body positions 
(horizontal during implantation vs vertical during 
X-ray examination). In most patients (n = 14; 
58.3%), AS rings were localized in region 2 and 1 
(n = 5; 28%). Details on AS rings localizations 
and mean atrial signal amplitude are presented in 
Figure 1. We observed significantly greater AS am-
plitude for regions 1 and 2 when compared with oth-
er regions (in fact 3 and 4) (3.15 vs. 1.2, p = 0.045, 
7.53 vs. 3.8, p < 0.001 and 5.63 vs. 2.44; p = 0.017 
for periprocedural measurements, IHFU and AFU, 
respectively).
We found significant, negative correlation of: 
AS-AFU and RADl (r = –0.46; p = 0.02), AS-PP 
and RADs (r = –0.56, p = 0.02), AS-AFU and RADs 
(r = –0.48, p = 0.02), AS-IHFU and RAA (r = –0.45, 
p < 0.05), and AS-AFU and RAA (and r = –0.52, 
p < 0.01). There were no other significant corre-
lations with other echocardiographic parameters 
listed in Table 1.
When echocardiographic parameters were 
compared with radiographic region localization, 
no significant correlation with multiple right ven-
tricular dimensions was found.
Discussion
DX system is a unique technique in the era of 
ICDs. Until now, we have not had any data about 
periprocedural approach to optimization of AS. 
There are also no guidelines for patient selection 
for single-lead dual chamber ICD system. Our 
study investigated a probable relationship between 
floating atrial dipole position, as well as RA dimen-
sions and AS in a population of patient who received 
single-lead dual chamber ICD. The major finding 
of our study is the negative correlation between 
RA size and the dependence of AS amplitude and 
floating dipole position in the RA.
Literature in the subject is very limited. 
Iori et al. [21] showed stable AS during 200-day 
follow-up but the population of the study was 
limited to only 13 patients. In the largest, so far, 
multicenter study including 116 patients with ICD 
DX system, Safak et al. [22] achieved appropriate 
AS in 93.8% of patients. In this study, mean pre-
amplified P-wave amplitudes ranged from 5.0 mV 
to 6.1 mV. In our set of patients, mean pream-
plified AS during the implantation procedure 
was 2.7 mV (0.7–6.7 mV). During follow-up, in 
1 patient, despite programing maximal sensitiv-
Table 1. Baseline characteristics of the study 
population.
Age [years] 62 ± 13
Male 24/100%
Height [cm] 173 ± 6.5
Weight [kg] 76.5 ± 17.0
Indication 
Dilated cardiomyopathy 8.3%
ischemic cardiomyopathy 91.7%
NYHA I 4.2%
NYHA II 66.6%
NYHA III 29.2%
NYHA IV 0.0%
Primary prevention 79.2%
Secondary prevention 20.8%
Medical history
Hypertension 58.3%
Dyslipidemia 58.3%
CKD (eGFR < 60 mL/min) 33.3%
Type 2 diabetes mellitus 33.3%
Atrial fibrillation 8.3%
Atrial sensing [mV]
Periprocedural 2.72 ± 1.76
In-hospital follow-up 6.72 ± 2.45
Ambulatory follow-up 4.97 ± 2.75
Chest X-ray
Dipole position: 
1 20.8%
2 58.3%
3 12.5%
4 8.3%
5 0.0%
6 0.0%
Echocardiography
RADl [cm] 4.94 ± 0.76
RADs [cm] 4.13 ± 0.71
RAA [cm2] 17.99 ± 5.48
RVD RVOT 1 [cm] 3.08 ± 0.42
RVD RVOT 2 [cm] 2.77 ± 0.41
RVD AP4C 1 [cm] 4.04 ± 0.69
RVD AP4C 2 [cm] 3.04 ± 0.42
RVD AP4C 3 [cm] 7.56 ± 1.17
LVEF [%] 28.00 ± 9.39
CKD — chronic kidney disease; eGFR — estimated glomerular 
filtration rate; NYHA — New York Heart Association; RADL — right 
atrium diameter long; RADs — right atrium diameter short; RAA —  
right atrium area; RVD — right ventricle diameter; RVOT — right 
ventricular outflow tract; AP4C — apical 4-chamber; LVEF — left 
ventricular ejection fraction
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ity, we did not achieve reliable AS and the atrial 
channel was turned off.
Supraventricular arrhythmias, mainly AF, are 
more common in subjects with HF and are as-
sociated with worse prognosis in this population 
[5, 6]. Identification of patients at risk of future 
thromboembolic events associated with silent AF 
is a challenge. Use of monitoring of atrial electrical 
activity offers potential opportunity to identify such 
patients. In the ASSERT study, including patients 
with dual chamber pacemakers, it was demon-
strated that subclinical AF of ≥ 6 min duration 
was associated with 2.5-fold higher risk of stroke 
and systemic thromboembolism [23]. AF remains 
also the main cause of inappropriate therapies of 
ICDs [7, 8]. Proper AS plays a crucial role in both 
arrhythmia discrimination and supraventricular 
arrhythmia diagnostics. Inadequate AS may give 
inappropriate result of arrhythmia discrimination 
algorithm and trigger cardioversion delivery in 
case of supraventricular tachycardia. To receive 
adequate AS with floating dipole ICD it is advisable 
to use fourfold amplifier and special filtering of na-
tive signal. Enlargement of the atria was identified 
as a factor of higher prevalence of AF and lower 
likelihood of sinus rhythm restoration and mainte-
nance [24, 25]. Former studies have shown that the 
size of atria is correlated with mean AS amplitude 
and AS stability in VDD pacemakers [26, 27]. This 
finding is consistent with our observations in this 
ICD population. It makes a paradoxical situation 
where the larger the atria the greater the risk of 
atrial undersensing and malfunction of the device. 
One cannot foresee the amplitude of f-wave dur-
ing ICD implantation. Programing of achievably 
maximal sensitivity seems to be important in this 
population. In some patients during follow-up, loss 
of AS in device diagnostics may be suggestive for 
an AF episode.
Possible relationship between patients’ height 
and AS amplitude was suggested [22]. In the pre-
sent study, we did not find any connection between 
these variables. In our opinion, height may influ-
ence the choice of length of an electrode but should 
not have any significant impact on sensing.
Potentially useful techniques to achieve bet-
ter AS owing to higher position of sensing dipole 
are the following: 1) using defibrillation leads with 
dipole located 17 cm from the tip of an electrode in 
enlarged hearts, 2) implantation of a lead to alterna-
tive places instead of right ventricle apex, and 
3) playing with the course of an lead in RA (greater 
“heel” vs. more tense).
Limitations of the study
Our study has several limitations. First, the 
study population was relatively small, thus some 
analyses were underpowered to detect significant 
differences. We realize that results in a relatively 
small population sample may be significantly af-
fected by a single measurement and there is a need 
for future investigation in a larger cohort of patients 
to better asses the relationships between atrial 
sensing and atrium diameter. Second, we analyzed 
only mean AS amplitude during normal breathing 
in lying position during the implantation proce-
dure and in sitting position during predischarge 
and ambulatory follow-up. It is unknown whether 
results of AS test in different body positions would 
affect the results of our study. Third, standard chest 
X-ray examination is performed in standing position 
during maximal inspiration, therefore the sens-
ing dipole position may slightly differ in different 
circumstances.
Conclusions
Smaller dimensions of RA and higher posi- 
tion of floating dipole in the RA are predictors of 
better AS amplitude in single-lead dual chamber 
ICDs.
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